Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 531 to 540 of 875

TitleReference numberPublishedLast updated
Regorafenib for previously treated advanced hepatocellular carcinomaTA555
Darvadstrocel for treating complex perianal fistulas in Crohn's diseaseTA556
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemiaTA552
Lenvatinib for untreated advanced hepatocellular carcinomaTA551
Vandetanib for treating medullary thyroid cancerTA550
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)TA548
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Tofacitinib for moderately to severely active ulcerative colitisTA547
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545

Results per page

  1. 10
  2. 25
  3. 50
  4. All